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ABSTRACT
Background: Staphylococcus aureus is still considered one of the most significant
human pathogens in terms of morbidity, mortality, and costs. Vancomycin should be
avoided if possible for the treatment of MRSA when the Minimum Inhibiting
Concentration (MIC) to Vancomycin is 2µg/mL, as it poses a therapeutic challenge. Main
therapeutic options include Daptomycin and Linezolid, two new, expensive drugs, and
trimethoprim/sulfamethoxazole(TMP/SMX), an old, inexpensive agent. Study aims were
to compare the clinical efficacy and potential cost savings associated with TMP/SMX
use.
Methods: A retrospective study was conducted at Detroit Medical Center. For calendar
year 2009, unique adult patients (>18 years) with infections due to MRSA with MIC to
Vancomycin of 2 µg/mL were included if they received ≥2 doses of TMP/SMX and/or
Daptomycin and/or Linezolid. Data were abstracted from patient charts and pharmacy
records.
Results: There were 328 patients included in study cohort; 143 received TMP/SMX
alone, 89 received Daptomycin alone, 75 received Linezolid alone, and 21 patients
received a combination therapy. In bivariate analysis, patients on TMP/SMX had
significantly better outcomes, including in-hospital (p=0.003) and 90-day mortality
(p<0.001). Patients on TMP/SMX were also younger (p<0.001), with less co-morbidities
(p<0.001), less severe disease states (p<0.001), and lower intervals to initiation of
appropriate therapy (p=0.001). In multivariate models, both with/without the use of a
propensity score, the association between TMP/SMX treatment and mortality was no
longer significant, but ORs remained lower than 1. Cost savings of using TMP/SMX
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averaged $2,067 per patient. The susceptibility rate to TMP/SMX had significantly
increased from 2005 to 2009, despite increased usage.
Conclusions: TMP/SMX compared favorably with Linezolid and Daptomycin in terms
of efficacy and mortality. Cost saving were enormous. TMP/SMX use should be
considered, particularly for skin and soft-tissue infections, and even in severe disease
states due to MRSA with elevated vancomycin MICs.
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CHAPTER 1: INTRODUCTION AND BACKGROUND
Introduction
Methicillin-resistant Staphyloccus aureus (MRSA) is a deadly human pathogen,25
and Vancomycin is considered the therapeutic option of choice.27 In recent years, the
minimal inhibitory concentrations (MIC) to Vancomycin have been increasing in MRSA
isolates.11,29,39 Recent data demonstrated higher rates of clinical and bacteriological
failures with Vancomycin treatment against MRSA strains, which have Vancomycin
MIC ≥ 2 µg/mL.11,15,18,27,29,39,44,45 The options to treat MRSA infections when the
vancomycin MIC are ≥ 2 µg/mL include “new” and expensive agents that were
extensively studied for the treatment of MRSA infections, like daptomycin or linezolid,
or “older,” generic, inexpensive agents like trimethoprim/sulfamethoxazole (TMP/SMX),
clindamycin, or fusidic acid. There are scant clinical data comparing the “new” widely
used agents to the “old” agents; therefore, management decisions are not based on solid
scientific data. Clindamycin is a bacteriostatic agent that has strong correlation to
Clostridium difficile infections,25 and therefore prescribers are reluctant to use it as a
single agent for severe invasive MRSA infections, particularly for prolonged courses.25
While fusidic acid has recently become available in the US, clinical efficacy data are
lacking16 and rapid emergence of resistance when given as monotherapy is a major
concern.20 TMP/SMX, despite being used against S. aureus for many years, has not been
extensively studied in controlled trials for this indication.26
Background
The emergence of antibiotic resistance is an evolutionary process that is based on
selection for organisms that have enhanced ability to survive doses of antibiotics that
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would have previously been lethal.3 The primary causes of antimicrobial resistance
include:
•

The widespread use of antibiotics both inside and outside of medicine; and

•

The misuse and overuse of antibiotics by doctors, other health personnel, and
patients.
Staphylococcus aureus is recognized as a cause of a wide range of infections,

from minor skin infections and chronic bone infections to devastating septicemia and
endocarditis.1,37 Significant events in the evolution of S. aureus have included the
development of community strains of S. aureus that are methicillin resistant (MethicillinResistant S. aureus, MRSA) but also harbor genes associated with increased virulence.13
MRSA alone (which probably accounts for fewer than one-third of all S. aureus
infections) caused more deaths in the United States in 2005 than human
immunodeficiency virus infection (estimated MRSA mortality rate in 2005 of 6.3 per
100,000 individuals) and caused more invasive infections (estimated MRSA incidence in
2005 of 31.8 per 100,000 individuals) than other important bacterial pathogens such as
Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitides.7.50
Vancomycin was the “therapy of choice” for treating MRSA. However, the emergence of
Vancomycin-resistant Enterococcus (VRE), Vancomycin-intermediate S. aureus (VISA)
and vancomycin-resistant S. aureus (VRSA) in several countries13 further reduced the
treatment options.
The Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS) defined
breakpoints for MIC and disc diffusion testing of vancomycin against S. aureus over 20
years ago.10 In 2006, the CLSI redefined vancomycin breakpoints as follows: susceptible
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at a vancomycin broth MIC of < 2µg/mL, intermediate at a vancomycin broth MIC of
>16µg/mL.
In recent years, the minimum inhibiting concentrations (MICs) to vancomycin
have been increasing in MRSA isolates, as reflected by increments in MIC50 and MIC90
reported on antibiograms from various centers around the world, with the main
mechanism being heteroresistant vancomycin-intermediate Staphylococus aureus
(hVISA).11 This “MIC creep” has been validated by showing how the fraction of hVISA
isolates increase with increasing vancomycin MICs.40 As mentioned earlier, accumulated
data demonstrates higher rates of clinical and bacteriological failures with vancomycin
treatment against MRSA strains, which have vancomycin MIC ≥ 2 µg/mL.11,15,18,29,39,44,45
Therefore, whenever prescribers are confronted with MRSA with vancomycin MIC of 2
µg/mL, they are placed in a crucial junction in terms of management decision: they can
choose to use new and expensive agents that were extensively studied for the treatment of
MRSA infections, like daptomycing or linezolid, or they can choose to use older, generic,
inexpensive agents like trimethoprim/sulfamethoxazole (TMP/SMX) or clindamycin that
were less studied against MRSA infections. There are scant clinical data comparing the
“new” agents to the “old” agents, and therefore prescribers cannot base their decision on
solid scientific data and are also reluctant to use Clindamycin as a single agent for severe
MRSA infections, particularly for prolonged periods.25 TMP/SMX, despite being used
against S. aureus for many years, had not been extensively studied in controlled scientific
set-ups for this indication. A recent comparative retrospective trial of clindamycin versus
TMP/SMX for the treatment of mild skin and soft-tissue infections (SSTI) had
demonstrated the importance of incision and drainage in these syndromes but did not
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show any differences in terms of efficacy of the agents being used.21 A different trial
found TMP/SMX to be non-inferior to vancomycin for the treatment of MRSA
bacteremia in a region where most strains has a vancomycin MIC ≤ 1 µg/mL.22
The Detroit Medical Center (DMC) is located in the Southeast Michigan, which is
an endemic region for Acinetobacter baumannii (AB), carbapenem-resistant
enterobacteriaceae (CRE) and hetero-resistant vancomycin-intermediate Staphylococcus
aureus (hVISA), Methicillin-resistant Staphylococcus aureus (MRSA) and VISA
infections, with rates reported being amongst the highest in the country. And 10 out of
the 12 cases ever reported of vancomycin-resistant S. aureus (VRSA) in the US were
from this region.18
Study Objectives
Study aims were to:
1) Conduct a retrospective comparative trial of TMP/SMX versus Daptomycin or
Linezolid for the treatment of MRSA infections in Southeast Michigan, when the strain
has a Vancomycin minimum inhibiting concentration (MIC) of 2 µg/mL (including all
infectious clinical syndromes);
2) Analyze potential costs savings by using TMP/SMX instead of Daptomycin or
Linezolid when possible; and
3) Monitor the levels of drug susceptibilities in MRSA in light of the usage of these study
drugs in the past 5 years.
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Study Hypotheses
•

Trimethoprim/Sulfamethoxazole (TMP/SMX) treatment for hVISA will
not be associated with enhanced in-hospital mortality compared to
Daptomycin or Linezolid.

•

The trend of resistance rate of hVISA to TMP/SMX over the past years
does not significantly differ from the trend of resistance rate to
Daptomycin or Linezolid.

•

The costs associated with the use of TMP/SMX for treating hVISA will be
significantly lower than the costs associated with the use of Daptomycin
and/or Linezolid.
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CHAPTER 2: REVIEW OF LITERATURE
Co-trimoxazole (trimethoprim/sulfamethoxazole, TMP/SMX), an antibiotic in use
for several decades, has been shown to be active against S. aureus (including MRSA) in
vitro.24 Its components have synergistic bactericidal activity against S. auerus.19 The
susceptibility of MRSA isolates to co-trimoxazole increased from 73% in 1994-98 to
95% in 2001-04 in the USA.14
Evidence for clinical efficacy of co-trimoxazole in S. aureus infections is limited.
Only one randomized controlled trial has assessed co-trimoxazole for treatment of S.
aureus infections and was limited to an intravenous drug user population.26 In this study,
inferiority of co-trimoxazole to vancomycin was seen only for MRSA, while cure rate
and other clinical and microbiological outcomes were similar for both drugs against the
MRSA group.
Other evidence for the efficacy of co-trimoxazole in S. aureus infections is
limited to small non-randomized studies, animal studies, and case reports. Successful
treatment of S. aureus endocarditis, meningitis, and other osteomyelitis with cotrimoxazole has been reported8,9,12,26,30,31,33 and a few cases of right-sided MRSA
endocarditis were included in the randomized trial. However, co-trimoxazole treatment
was inferior to cloxacillin, teicoplanin, and vancomycin in an animal model of S. aureus
aortic endocarditis.17 Two reviews attempting to summarize the data concerning cotrimoxazole treatment for S. aureus infections emphasize the need for further clinical
studies comparing this drug with other available options, specifically vancomycin.5,6
In 2001, Fridkin reviewed the U.S. experience with VISA (defined at the time as
MRSA clinical isolates with vancomycin MICs of 8 to 16µg/mL). Six patients were
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discussed, some previously reported. Five patients died, but only one died directly from
MRSA sepsis, and this patient was a dialysis patient with line sepsis. Of the other
patients, one patient treated with surgical drainage plus linezolid, trimethoprimsulfamethoxazole (TMP/SMX), and doxycycline survived. The remaining 4 patients
either refused surgical treatment or were cured of MRSA before death from another
cause.4 For the survivor, weekly serum vancomycin levels were in the range of 2.7 to 4.9
µg/mL during the 10 weeks prior to the detection of VISA in peritoneal fluid.49
Khosrovaneh et al. described 22 patients with recurrent or persistent MRSA
bacteremia in Detroit, MI.48 Patient isolates were specifically examined for hVISA using
a PAP/AUC ratio of > 0.9. Khosrovaneh et al., while observing that isolates with higher
initial MICs (in the vicinity of 4 µg/mL) were more likely to produce subcolonies with
even higher MICs, detected definite hVISA in only 3 of their 22 patients and concluded
that hVISA defined in this way was uncommon and that treatment failure could be
explained by other factors without the need to invoke the presence of resistant
subpopulations per se. 48
In a retrospective cohort study from Texas, Maclayton et al. studied patients
undergoing hemodialysis who developed MRSA bacteremia, and these researchers also
attempted to relate outcomes to initial MICs. In the univariate analysis, MICs of <0.5
µg/mL predicted improved survival, but recent surgery and ICU admission were also risk
factors for having MRSA isolates with MICs of 2 µg/mL. The MIC method was not
defined. In a multivariate analysis that included cost modeling, patients with high-MIC
isolates had increased lengths of stay and increased hospital costs compared with patients
with low-MIC isolates and uninfected control patients, but mortality was not increased.42
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A further recent report suggested that prior glycopeptides exposure is associated with
increased MICs and reduced in vitro vancomycin killing in patients who subsequently
developed MRSA sepsis.47
In another retrospective cohort study conducted in February 2010 from Israel,
Elad Goldberg et al. studied the efficacy and safety of co-trimethoxazole to Vancomycin
in adult patients with MRSA bacteremia. The outcomes collected were 30-day mortality,
persistent bacteremia (defined as positive blood culture (BC) > 14 days after the first
positive BC, but within 30 days), relapse (defined as recurrence of the same phenotype >
30 days after the first positive BC within 12 months), and adverse events. And within the
limitations of a small retrospective study, the study concluded that co-trimoxazole had a
safety and efficacy profile similar to that of vancomycin and may offer an attractive
additional therapeutic option for MRSA bacteremia. The data from these clinical studies
show that Co-trimoxazole is comparatively effective and safe to treat S. aureus infections
compared to the treatment methods available on market.
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CHAPTER 3: RESEARCH DESIGN AND METHODOLOGY
Setting
This study was conducted at Detroit Medical Center, an 8-hospital healthcare
system with >2,200 inpatient beds, located in Southeast Michigan. The dedicated
departments involved in the study include Division of Infectious Diseases, Department of
Pharmacy Services, Department of Clinical Microbiology, and Anti-Infective Research
Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit
Medical Center, and Wayne State University, Detroit, MI.
Study Design
This was an unblinded, retrospective study analyzing existing hospital medical
records to extract data of adult patients infected with hVISA/MRSA who have received
TMP/SMX and/or Daptomycin or Linezolid, seen at Detroit Medical Center (DMC).
Prior to initiation of this study, approvals were obtained from Institutional Review Board
of DMC, Human Investigation Committee, and Wayne State University, and later Eastern
Michigan University’s Human Subjects Review Committee approved this project’s
proposal. A waiver of the consent was granted for this study.
Study Population
Three hundred and twenty-eight patients were identified over a one-year period
(January 1, 2009, through December 31, 2009) and were included in a retrospective
cohort study of outcomes associated with infections caused by MRSA with vancomycin
MIC of 2µg/mL. Of those, 143 received TMP/SMX alone, 89 received Daptomycin
alone, 75 received Linezolid alone, and 21 patients received a combination therapy.
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Adult patients (>18 years) who received ≥2 doses of either TMP/SMX or
daptomycin or linezolid from 3 days prior to 14 days after their culture date were
included. Colonization cases (based of absence of SIRS criteria18 or of attending
physician clinical discretion) were excluded, and only unique patient infectious episodes
were analyzed.
Data Collection
Variables collected for each patient included 1) demographics; 2) co-morbidities
(including Charlson’s scores34); 3) microbiologic data; 4) acute illness indices (including
McCabe score36); 5) time to initiation of appropriate therapy per in-vitro susceptibility
results, and 6) outcomes: in-hospital and 30-days mortality, length of hospital stay (LOS),
functional status deterioration in >1 activities of daily living,41 discharge to a long-term
care facility (LTCF) after being admitted from home, additional hospitalization in the
following 6 months, additional isolations of the same organism in the following 3 months
(i.e. “bacteriologic failures”), and costs of the antibiotic regimen prescribed.
Antimicrobial costs and usage of study drugs within the health system, in defined daily
doses (DDD) for the years 2005-2009, were obtained from pharmacy records.
DMC central microbiology laboratory processes, on average, 500,000 samples
annually. Bacteria were identified to the species level, and susceptibilities were
determined to pre-defined antimicrobials, based on an automated broth microdilution
system (MicroScan™; Siemens AG; Germany) and in accordance with Clinical and
Laboratory Standard Institutions (CLSI) criteria and breakpoints.2 Daptomycin
susceptibility was added to the automated system panel in 2008. Prior to 2008, E-tests
(bioMérieux, France) were used to determine daptomycin susceptibility and were done
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inconsistently upon specific requests. MRSA antibiograms for the years 2005-2009 were
conducted according to the revised CLSI criteria issued in 2007.2
Data Analysis
Statistical analyses were performed by using IBM-SPSS 19 (2011) and Epi Info™
(version 6.0). Conditional logistic regression tests were used for multivariate analyses.
Chi-square test for trend and Spearman correlation test were used to analyze trends of
MRSA prevalence, incidence (per 1,000 patient days), susceptibility rate to study drugs,
drug usage, and correlation between drug usage and the prevalence and incidence of
MRSA isolation and the susceptibility rates to study drugs, all for the years 2005-2009.
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CHAPTER 4: RESULTS
There were 328 patients infected with MRSA with vancomycin MIC of 2 µg/mL
during 2009 that received one of the study drugs and met all inclusion criteria. Twentytwo of the patients had a catheter-related bloodstream infection (BSI), 42 had BSI
without an identifiable source, 90 had pneumonia, 11 had urinary tract infection, and 145
had skin and soft-tissue infection (SSTI). Overall, 143 received TMP/SMX alone, 89
received daptomycin alone, 75 received linezolid alone, and 21 patients received a
combination of TMP/SMX with either daptomycin or linezolid. Of the entire cohort, 5
(1.5%) isolates were non-susceptible to TMP/SMX. All isolates were susceptible to
daptomycin (mean MIC=0.5 ±0.4 µg/mL) and linezolid (mean MIC=2.5 ±0.9 µg/mL).
The univariate analysis between patients based on the anti-MRSA regimen is displayed in
Table 1. TMP/SMX was associated with significant favorable outcomes (including all
outcomes captured) compared to the other regimens prescribed (bottom of Table 1).
However, TMP/SMX was also prescribed to an entirely different population, which
consisted of younger individuals (48±5 vs. 56.3 years, p<0.001) with lower Charlson’s
scores (p<0.001), better McCabe scores (p<0.001), more commonly SSTIs (p<0.001),
less commonly BSI (p<0.001), and lower severity of sepsis levels (p<0.001).5 Moreover,
patients who received TMP/SMX had significantly shorter intervals to initiation of
appropriate therapy (62±71.7 vs. 93.3±62.8 hours, p<0.001), which is considered the
strongest modifiable factor associated with reduced mortality in severe sepsis.46
Multivariate analysis was conducted for in-hospital mortality; parameters inserted into
the model included 1) age (dichotomized to > 55 and ≤ 55 years), 2) Charlson’s
combined condition score (dichotomized to > 4 and ≤ 4 co-morbidities), 3) the infectious
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clinical syndrome (dichotomized to SSTI vs. other clinical syndromes), 4) level of sepsis
(dichotomized to sepsis syndrome vs. severe sepsis / septic shock / multi-organ failure),
5) time to initiation of appropriate therapy (dichotomized to > 80 and ≤ 80 hours), and 6)
the anti-MRSA therapy administered (dichotomized to patients receiving TMP/SMX vs.
those who did not). TMP/SMX was not associated with in-hospital mortality in
multivariate analysis (OR=0.6, CI-95%=0.2-1.7, p=0.34).
Table 1:
Bivariate analysis of patients treated with trimethoprim/sulfamethoxazole (TMP/SMX),
daptomycin, linezolid, or combination of TMP/SMX with either daptomycin or with
linezolid, for infections caused by methicillin-resistant Staphylococcus aureus with MIC
of 2 µg/mL to vancomycin, Detroit Medical Center, 2009
Parameter
TMP/SMX Daptomycin Linezolid Combination
P
of TMP/SMX value
therapy
therapy
therapy
plus
(n=75)
(n=89)
(n=143)
daptomycin or
linezolid
(n=21)
Demographics
Male sex
86 (60%)
56 (63%)
40 (53%)
11 (52%)
0.57
Age, years (mean ±
47.6±18
57±17
56±16
55±14
<0.001
SD)
Elderly (≥65 years)
26 (18%)
26 (29%)
18 (24%)
4 (19%)
0.3
African American
102 (71%)
57 (64%)
42 (56%)
16 (76%)
0.08
LTCF permanent
16 (11%)
29 (33%)
16 (21%)
3 (14%)
0.001
residence
Background Chronic conditions
Hemodialysis
2 (1.4%)
27 (30%)
4 (5%)
3 (14%)
<0.001
Ischemic heart
16 (11%)
23 (26%)
26 (35%)
3 (14%)
<0.001
disease
Congestive heart
19 (13%)
31 (35%)
25 (33%)
7 (33%)
<0.001
failure
Peripheral vascular
15 (11%)
23 (26%)
14 (19%)
4 (19%)
0.02
disease
Diabetes Mellitus
34 (24%)
35 (39%)
29 (39%)
8 (38%)
0.04
17 (12%)
49 (55%)
25 (33%)
6 (29%)
<0.001
Chronic renal failure
A

Chronic lung disease

38 (27%)

31 (35%)

52 (69%)

9 (43%)

<0.001

15 (11%)
10 (7%)

28 (32%)
14 (16%)

28 (37%)
18 (24%)

3 (14%)
5 (24%)

<0.001
0.003

B

Peptic ulcer disease
Neurovascular
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disease C
Dementia
8 (6%)
Malignancy D
9 (6%)
HIV positive
10 (7%)
Charlson’s [19]
2.2±2.6
weighted index co
morbidity
Charlson’s [19]
3.1±3.1
combined condition
score
Charlson’s [19] 1065±40
year survival
probability, percents
Culture body site
Blood
3 (2%)
Respiratory
28 (20%)
Urine
17 (12%)
Wound
94 (66%)
Infectious Clinical Syndrome
Catheter-related
0
bloodstream
infection
Bacteremia without
3 (2%)
a determined focus
Pneumonia
24 (17%)
Urinary tract
15 (11%)
infection
Skin and soft-tissue
95 (66%)
infection
Status on admission
Dependent
33 (23%)
E
functional status
Reduced
22 (15%)
consciousness
Permanent/chronic
35 (25%)
F
invasive device
Acute illness indices
McCabe score [20]
2.8±0.5
(mean ± SD)
Rapidly fatal state
4 (5%)
per McCabe score
[20]
High severity of
21 (18%)
sepsis level [18]
Necessitates transfer
18 (14%)

8 (9%)
18 (20%)
1 (1%)
4.3±3.3

13 (17%)
14 (19%)
1 (1%)
4.9±3.6

1 (5%)
1 (5%)
1 (5%)
3.1±3

0.03
0.002
0.08
<0.001

5.8±3.9

6.4±3.9

4.4±3

<0.001

36±39

30±39

50±35

<0.001

62 (70%)
3 (3%)
3 (3%)
16 (18%)

8 (11%)
45 (60%)
2 (3%)
18 (24%)

6 (29%)
7 (33%)
0
7 (33%)

<0.001
<0.001
0.01
<0.001

16 (18%)

3 (4%)

3 (14%)

<0.001

28 (32%)

5 (7%)

4 (19%)

<0.001

6 (7%)
1 (1%)

47 (63%)
2 (3%)

8 (38%)
2 (10%)

<0.001
0.002

33 (37%)

12 (16%)

5 (24%)

<0.001

41 (46%)

35 (47%)

5 (24%)

<0.001

29 (33%)

22 (29%)

4 (19%)

0.012

62 (70%)

57 (76%)

14 (67%)

<0.001

2.5±0.7

2.3±0.7

2.5±0.8

<0.001

5 (10%)

6 (13%)

1 (17%)

0.01

46 (54%)

33 (48%)

10 (48%)

<0.001

18 (23%)

31 (55%)

9 (47%)

<0.001
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to an ICU
Hours to effective
therapy G (mean ±
SD)
Outcomes
In hospital death
Died in 3 months
Functional status
deterioration E
Discharged to LTCF

61±72

90±58

97±68

76±73

0.001

5 (3.5%)
7 (6%)
8 (6%)

9 (10%)
10 (13%)
17 (19%)

14 (19%)
18 (30%)
22 (30%)

2 (9.5%)
3 (16%)
9 (43%)

0.003
<0.001
<0.001

14 (11%)

14 (20%)

20 (36%)

8 (50%)

<0.001

51 (36%)

42 (48%)

36 (50%)

15 (75%)

0.005

5 (3.5%)

11 (13%)

15 (20%)

4 (19%)

<0.001

7±32

12±42

22±18

19±12

0.006

7±9

12±10

17±13

18±12

<0.001

7±9

12±9

17±14

16±11

<0.001

H

Additional
hospitalizations I
Bacteriologic failure
J

Total LOS, days
(mean ± SD)
LOS from culture to
discharge, days
(mean ± SD)
LOS from culture to
discharge, after
excluding the dead,
days (mean ± SD)

Note. LTCF= long-term care facility; HIV= human immunodeficiency virus; ICU= intensive-care unit;
LOS= length of hospital stay;
A
chronic renal failure was defined as serum creatinine above 1.5mg%.
B
includes chronic obstructive pulmonary disease (COPD), bronchiectasis, restrictive lung disease, and
asthma, among others.
C
any cerebral stroke in the past (whether with neurologic sequel or not)
D
includes both active and past malignancy
E
measured according to Kats criteria, of being or becoming dependent in ≥1 activities of daily living [21].
F
include permanent devices like tracheotomies, central lines, urinary catheters, external orthopedic devices,
gastrostomy, that were in place at least 48 hours prior to MRSA isolation.
G
effective therapy defined as therapy that the isolate displays susceptibility to per in-vitro testing
H
discharge to a facility after initially being admitted from home
I
additional hospitalizations in the 6 months following the MRSA isolation
J
additional MRSA isolations with vancomycin MIC of 2 µg/mL 14 days to 1 year following the index
culture

Six other multivariate models were constructed for each of the other outcomes: 1)
3 months mortality; 2) LOS from infection to discharge of > 10 days (excluding the
patients who died); 3) functional status deterioration; 4) discharged to LTCF after being
admitted from home; 5) additional hospitalization; and 6) bacteriologic failures. For each
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model, the same parameters as displayed for the in-hospital mortality model were
incorporated. TMP/SMX was no longer significantly associated with any one of these
outcomes, although all odds ratios (OR) remained < 1 (data not shown).
In order to try to further explore the potential impact of TMP/SMX on mortality,
compared to the “newer” agents, a propensity score analysis was conducted. Patients who
received TMP/SMX alone or in combination (n=164) were compared to patients who
have not received TMP/SMX (n=164). The probability of receiving TMP/SMX
(“propensity”) was estimated using a multivariate logistic regression model. Based on the
β-coefficients of the final model, a propensity score was developed: 1) Charlson’s
combined condition score > 4 and hours to effective therapy > 80 were assigned 2 points
each; 2) high level of sepsis (severe sepsis / septic shock / multi-organ failure) was
assigned 2.5 points; and 3) SSTI was assigned 3 points.
The propensity score of receiving TMP/SMX was calculated for each patient. In
multivariate analysis for in-hospital mortality, the impact of the anti-MRSA therapy
(dichotomized to patients receiving TMP/SMX vs. those who did not) on mortality was
controlled for the propensity score. TMP/SMX was again not significantly associated
with in-hospital mortality (OR=0.62, CI-95%=0.26-1.5, p=0.3).
One of the potential clinical niches for TMP/SMX treatment is SSTIs. In the subgroup of 145 SSTI cases, TMP/SMX alone was prescribed to 95 patients; daptomycin
alone to 33 patients, linezolid alone to 12 patients, and 5 patients with SSTI had received
TMP/SMX with either daptomycin or linezolid. In the univariate analysis, TMP/SMX
was again associated with favorable outcomes including in-hospital mortality (none of
the patients who received TMP/SMX had died, vs. 4 in the daptomycin group, OR=0.9,
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CI-95%= 0.83-0.99, p=0.002), 3-months mortality (OR=0.89, CI-95%= 0.81-0.99,
p=0.002), LOS from culture to discharge after excluding the patients who died (4.2±5.6
vs. 10.2±9.6 days, p<0.001), discharge to LTCF after being admitted from home
(OR=0.3, CI-95%= 0.07-0.9, p=0.03), and bacteriologic failures (p<0.001). However, as
in the general cohort, among the SSTI group of patients, TMP/SMX was prescribed to
younger individuals (p<0.001) with lower Charlson’s scores (p<0.001), better McCabe
scores (p=0.003), lower indices of acute sepsis levels (p<0.001), and shorter intervals to
initiation of appropriate therapy (p=0.004). No multivariate analyses for mortality could
have been conducted to control for these confounders (none of the patients who received
TMP/SMX had died). In the multivariate models of the other outcomes that were
significant in the univariate analysis, with the same variables as mentioned for the general
cohort entered into the models, TMP/SMX was no longer significantly associated with
any of the outcomes, though all OR remained < 1 (data not shown).
Figure 1 displays the prevalence of MRSA, the usage in DDD of all study drugs,
and the susceptibility rates (in percents) of MRSA to all study drugs, for the years 2005
to 2009. The incidence of MRSA isolations had remained stable during the study years
(7.5±0.23 cases per 1,000 patient days, p for trend=0.7), along with insignificant
increments in TMP/SMX usage (14,630±5,135 DDD per year, p for trend=0.7),
daptomycin usage (4,620±3,595 DDD per year, p for trend=0.2), and linezolid usage
(4,416±2,486 DDD per year, p for trend=0.9). The susceptibility rate to linezolid (mean
of 99.9±0.05% per year, p for trend=0.08) and daptomycin (mean of 99.8±0.07% per
year, p for trend=0.3) had insignificant increments, and the susceptibility rate to
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TMP/SMX had a significant increment during the 5-year study period (mean
susceptibility rate of 98.3±0.3% per year, p for trend=0.048).
The antibiotic course in the daptomycin (n=89) and linezolid (n=75) groups of
patients had cost $2,486±2,576 and $1,670±1,414 per patient, respectively (mean number
of treatment days with daptomycin was 12.3±11.5 days and with linezolid 9.6±8.3 days).
In the group who received TMP/SMX (n=143), the antibiotic course had cost $27±44 per
patient (mean number of treatment days was 5.5±5.8). The difference between the groups
was statistically significant (p<0.001). There were 161 patients (49% of the entire cohort)
who had an isolate that was susceptible to TMP/SMX but instead were treated with
daptomycin or with linezolid. If these patients had been treated instead with TMP/SMX
for the same number of treatment days that they received daptomycin or linezolid, the
total cost savings would have been $332,844.20, for an average of $2,067.40 per patient.
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Figure 1. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) isolations,
coupled with the rate of susceptibility and level of usage (in defined daily doses) to
trimethoprim / sulfamethoxazole, daptomycin and linezolid, Detroit Medical Center,
2005-2009.
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CHAPTER 5: CONCLUSIONS
In the past 2 years, two pivotal clinical practice guidelines have been published by
the Infectious Diseases Society of America (IDSA) and other related professional
societies: 1) treatment guidelines for MRSA infections25 and 2) therapeutic guidelines for
vancomycin usage.27 Both guidelines pointed to a commonly encountered gap in current
scientific knowledge, pertaining to the preferred management of MRSA infections when
the isolate’s vancomycin MIC is of 2 µg/mL or above. A recent publication even
questioned whether vancomycin might still be an option to treat these pathogens.23 This
study analyzed a large cohort of infected patients during a 1-year period from an endemic
US location. The main finding was that prescribers are reluctant to use TMP/SMX for
severe MRSA infections and prefer to use drugs that are much more expensive, even
though their superiority over TMP/SMX has never been established or even investigated.
Despite the retrospective nature of the study, with all its inherent biases, the data suggest
non-inferiority of TMP/SMX compared to daptomycin or linezolid. Multivariate models,
with and without propensity scores, controlling in different ways for possible
confounders that might bias the true impact of the anti-MRSA therapy on outcomes,
revealed that TMP/SMX is at least as effective as the “newer” agents. Not just in-hospital
mortality was analyzed, but 6 additional outcomes were captured, with all multivariate
models displaying the same trend of results. Since the possibility of conducting a
prospective comparative randomized controlled clinical trial in the near future between
these “on-patent” drugs and TMP/SMX seems low, due to reluctance of pharmaceutical
companies to invest in such a trial, this study provides the most controlled data that could
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be obtained. Use of a propensity score, enabled to theoretically overcome inherited
biases, are inevitable in this type of comparative retrospective study design.
These analyses provide data pertaining to a commonly encountered clinical
scenario in many parts around the country and worldwide. Non-inferiority of TMP/SMX
compared to daptomycin or linezolid for the treatment of MRSA infections when the
vancomycin MIC is 2 µg/mL means that the latter agents can be preserved for severe
systemic infections. This will hopefully translate into reductions in emergence of
resistance to these 2 agents, which has already been described when these drugs were
extensively used in certain locations28,32. The potential costs reductions associated with
the use of the generic TMP/SMX proved to be enormous. Just for calendar year 2009 at
DMC, if patients infected with a susceptible isolate had been treated with TMP/SMX
instead of one of the other agents, this would have saved the healthcare system over
$330,000 just in antibiotic costs.
The fact that the susceptibility rates to all study drugs had increased at DMC for
the past 5 years (only the susceptibility to TMP/SMX had a significant increment),
averaging over 98% for all drugs, is reassuring (Figure 1). This is particularly important
in light of the fact that DMC’s antibiotic stewardship committee issued practice
guidelines back in 2007, recommending avoidance of the use of vancomycin for MRSA
infections when the MIC to the drug is ≥2 µg/mL. Still, despite this practice being
applied for almost 3 years, and despite the increase usages of TMP/SMX, daptomycin,
and linezolid in the past years (Figure 1), the drugs remain extremely active versus the
vast majority of MRSA strains. This is in accordance with a recent comprehensive
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systematic review that reported prolonged TMP/SMX use was not associated with
increments in antibiotic resistance.35
The sub-analysis of the group of patients with SSTIs points to a special niche
where TMP/SMX should be promoted, even in severe infections and in inpatients with
higher levels of acute illness indices. SSTI is the most common infectious clinical
syndrome caused by MRSA, and therefore using it for this indication will reduce the
burden of usage of the other expensive on-patent agents. In addition, the availability of
both parenteral and oral TMP/SMX preparations enables a natural step-down in treatment
and early hospital discharge when the patient stabilizes, an important factor in the
management of this infectious clinical syndrome. The unavailability in many locations
around the US and abroad in the past year of the parenteral preparation should be
addressed, so that when prescribers do want to use TMP/SMX, the parenteral drug should
be easily available.
The true significance of TMP/SMX nephrotoxicity (not the false elevations in
serum creatinine), along with the increased drug-drug interaction recently reported with
warfarin38 and other adverse events such as hyperkalemia,43 should all be further
explored and studied, particularly when the drug is being prescribed for prolonged
courses. Nevertheless, the drug is effective, cheap, and should be considered even in
severe disease states, in order to try to reduce the emergence of resistance and the costs
associated with over usage of daptomycin or linezolid.
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CHAPTER 6: LIMITATIONS OF THE STUDY
Limitations of this study included the following: (a) incomplete medical records
excluded some subjects from contributing to this study; (b) the possibility of observer
bias during data abstraction due to the unblinded nature of the study although the data
was analyzed by a statistician after data collection; (c) findings in this study may not be
generalizable to other community hospitals; and (d) study findings were not designed to
evaluate the patient’s needs for hospitalization or intensive monitoring or to evaluate
other medical conditions that may need further attention.
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